Synaptic Systems - Abeta-pE3

Cat. No.: 218 003

Amount: 50 µg

Price: $380.00

Cat. No. 218 003	50 µg specific antibody, lyophilized. Affinity purified with the immunogen. Albumin and azide were added for stabilization. For reconstitution add 50 µl H₂O to get a 1mg/ml solution in PBS. Then aliquot and store at -20°C to -80°C until use. Antibodies should be stored at +4°C when still lyophilized. Do not freeze!
Applications	WB: 1 : 1000 (see remarks) gallery IP: not tested yet ICC: not tested yet IHC: 1 : 500 (see remarks) gallery IHC-P: 1 : 200 (see remarks) gallery
Immunogen	Synthetic peptide corresponding to AA 3 to 7 from human Abeta-pE3 (UniProt Id: P05067)
Reactivity	Reacts with: human (P05067), rat (P08592), mouse (P12023). Other species not tested yet.
Specificity	Specific for Abeta-pE3.
Remarks	WB: Detects purified Abeta pE3. Complex samples like brain extracts still have to be tested. Boil membrane after blotting for 3min. IHC: Antigen retrieval with formic acid is required. IHC-P: Antigen retrieval with formic acid is required.
Data sheet	218_003.pdf

References for Abeta-pE3 - 218 003

WB (2)
ICC (2)
IHC (8)

A Screen of Plant-Based Natural Products Revealed That Quercetin Prevents Pyroglutamylated Amyloid-β (Aβ3(pE)-42) Uptake in Astrocytes As Well As Resulting Astrogliosis and Synaptic Dysfunction.
Arndt H, Bachurski M, Yuanxiang P, Franke K, Wessjohann LA, Kreutz MR, Grochowska KM
Molecular neurobiology (2024) : . 218 003 WB, ICC; tested species: rat

Prion-like behaviour and tau-dependent cytotoxicity of pyroglutamylated amyloid-β.
Nussbaum JM, Schilling S, Cynis H, Silva A, Swanson E, Wangsanut T, Tayler K, Wiltgen B, Hatami A, Rönicke R, Reymann K, et al.
Nature (2012) 4857400: 651-5. 218 003 IHC, WB

Posttranslational modification impact on the mechanism by which amyloid-β induces synaptic dysfunction.
Grochowska KM, Yuanxiang P, Bär J, Raman R, Brugal G, Sahu G, Schweizer M, Bikbaev A, Schilling S, Demuth HU, Kreutz MR, et al.
EMBO reports (2017) 186: 962-981. 218 003 ICC; tested species: rat

Novel Vaccine against Pathological Pyroglutamate-Modified Amyloid Beta for Prevention of Alzheimer's Disease.
Zagorski K, King O, Hovakimyan A, Petrushina I, Antonyan T, Chailyan G, Ghazaryan M, Hyrc KL, Chadarevian JP, Davtyan H, Blurton-Jones M, et al.
International journal of molecular sciences (2023) 2412: . 218 003 IHC; tested species: mouse

Brain pyroglutamate amyloid-β is produced by cathepsin B and is reduced by the cysteine protease inhibitor E64d, representing a potential Alzheimer's disease therapeutic.
Hook G, Yu J, Toneff T, Kindy M, Hook V
Journal of Alzheimer's disease : JAD (2014) 411: 129-49. 218 003 IHC; tested species: mouse

Glutaminyl cyclase in human cortex: correlation with (pGlu)-amyloid-β load and cognitive decline in Alzheimer's disease.
Morawski M, Schilling S, Kreuzberger M, Waniek A, Jäger C, Koch B, Cynis H, Kehlen A, Arendt T, Hartlage-Rübsamen M, Demuth HU, et al.
Journal of Alzheimer's disease : JAD (2014) 392: 385-400. 218 003 IHC; tested species: human

Glutaminyl cyclase-mediated toxicity of pyroglutamate-beta amyloid induces striatal neurodegeneration.
Becker A, Kohlmann S, Alexandru A, Jagla W, Canneva F, Bäuscher C, Cynis H, Sedlmeier R, Graubner S, Schilling S, Demuth HU, et al.
BMC neuroscience (2013) 14: 108. 218 003 IHC; tested species: human

Involvement of perineuronal and perisynaptic extracellular matrix in Alzheimer's disease neuropathology.
Morawski M, Brückner G, Jäger C, Seeger G, Matthews RT, Arendt T
Brain pathology (Zurich, Switzerland) (2012) 224: 547-61. 218 003 IHC; tested species: human

Selective hippocampal neurodegeneration in transgenic mice expressing small amounts of truncated Aβ is induced by pyroglutamate-Aβ formation.
Alexandru A, Jagla W, Graubner S, Becker A, Bäuscher C, Kohlmann S, Sedlmeier R, Raber KA, Cynis H, Rönicke R, Reymann KG, et al.
The Journal of neuroscience : the official journal of the Society for Neuroscience (2011) 3136: 12790-801. 218 003 IHC

Glutaminyl cyclase contributes to the formation of focal and diffuse pyroglutamate (pGlu)-Aβ deposits in hippocampus via distinct cellular mechanisms.
Hartlage-Rübsamen M, Morawski M, Waniek A, Jäger C, Zeitschel U, Koch B, Cynis H, Schilling S, Schliebs R, Demuth HU, Rossner S, et al.
Acta neuropathologica (2011) 1216: 705-19. 218 003 IHC

Cat. No.: 218 003

Amount: 50 µg

Price: $380.00

References
WB (2)
ICC (2)
IHC (8)

IHC

IHC-P

Background

Amyloid deposits, also called plaques, of Alzheimer's patients consist of several protein components like the amyloid beta-peptides (Abeta, Aβ) 1-40/42 and additional C- and N-terminally truncated and modified fragments. Very abundant are the isoaspartate (isoAsp)-Abeta and pyroglutamyl (pGlu)-Abeta peptides. The latter are formed by cyclization of the N-terminal glutamate at position 3 or 11 catalyzed by glutaminyl cyclase (QC) resulting in very amyloidogenic and neurotxic variants of Abeta; Abeta-pE3 and Abeta pE11.
In contrast to extracellular plaques that do not perfectly correlate with Alzheimer´s disease intraneuronal Abeta accumulation and vascular Abeta deposits have gained more and more evidence to be among the crucial factors responsible for progressive neuron loss.

1 ) Sullivan CP et al., Neurosci. Lett. (2011)
2 ) Perez-Garmendia R et al., J. Neuroimmunol. (2010)
3 ) Schilling S et al., Nat. Med. (2008)
4 ) Hook V et al., Biol. Chem. (2008)
5 ) Böhme L et al., Biol. Chem. (2008)
6 ) Schilling S et al., J. Neurochem. (2008)
7 ) Wiltfang J et al., J. Biol. Chem. (2001)
8 ) Wood SJ et al., J. Mol. Biol. (1996)
9 ) Kuo YM et al., J. Biol. Chem. (1996)

Protocols

AP Detection
ECL Detection
Fluorescent detection
Pre-adsorption protocol

IHC

Free floating
Slide mounted
Tissue preparation
Antigen retrieval
Pre-adsorption protocol

IHC-P

Chromogenic detection
Fluorescent detection
Tissue preparation
Pre-adsorption protocol

Other products for this target

Abeta-pE3 antibody - 218 003

References for Abeta-pE3 - 218 003